Related Experiment Video
Updated: Jan 30, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
LUBAC determines chemotherapy resistance in squamous cell lung cancer
E Josue Ruiz1, Markus E Diefenbacher1, Jessica K Nelson1
1Adult Stem Cell Laboratory, The Francis Crick Institute, London, UK.
Abstract:
Lung squamous cell carcinoma (LSCC) and adenocarcinoma (LADC) are the most common lung cancer subtypes. Molecular targeted treatments have improved LADC patient survival but are largely ineffective in LSCC. The tumor suppressor FBW7 is commonly mutated or down-regulated in human LSCC, and oncogenic KRasG12D activation combined with Fbxw7 inactivation in mice (KF model) caused both LSCC and LADC. Lineage-tracing experiments showed that CC10+, but not basal, cells are the cells of origin of LSCC in KF mice. KF LSCC tumors recapitulated human LSCC resistance to cisplatin-based chemotherapy, and we identified LUBAC-mediated NF-κB signaling as a determinant of chemotherapy resistance in human and mouse. Inhibition of NF-κB activation using TAK1 or LUBAC inhibitors resensitized LSCC tumors to cisplatin, suggesting a future avenue for LSCC patient treatment.
Insights
FBW7 inactivation drives lung cancer, with CC10+ cells originating squamous cell carcinoma. LUBAC-NF-κB signaling confers cisplatin resistance, offering a new therapeutic target for lung squamous cell carcinoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Lung squamous cell carcinoma (LSCC) and lung adenocarcinoma (LADC) are major lung cancer subtypes.
- Targeted therapies benefit LADC patients but show limited efficacy in LSCC.
- The tumor suppressor FBW7 is frequently altered in human LSCC.
Purpose of the Study:
- To investigate the role of FBW7 inactivation in lung cancer development.
- To identify the cell of origin for LSCC in a mouse model.
- To elucidate mechanisms of chemotherapy resistance in LSCC.
Main Methods:
- Utilized a mouse model with oncogenic KRasG12D and Fbxw7 inactivation (KF model).
- Employed lineage-tracing experiments to identify LSCC cell origins.
- Analyzed LUBAC-mediated NF-κB signaling in human and mouse LSCC.
Main Results:
- The KF model developed both LSCC and LADC.
- CC10+ cells, not basal cells, were identified as the origin of LSCC.
- LSCC tumors exhibited resistance to cisplatin, linked to LUBAC-NF-κB signaling.
- Inhibiting NF-κB activation resensitized tumors to cisplatin.
Conclusions:
- FBW7 inactivation is a key driver of LSCC and LADC.
- CC10+ cells are the progenitor cells for LSCC.
- LUBAC-mediated NF-κB signaling is crucial for LSCC chemoresistance.
- Targeting NF-κB signaling presents a promising therapeutic strategy for LSCC.
Related Concept Videos
Treatment Resistant Cancers
Lung Capacity
Resistivity
Resistance
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Determining the Plane of Cell Division
Animal cells
In animal cells, the cleavage furrow forms along the plane of cell division...

